HC Wainwright Cuts Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $9.00

Arcturus Therapeutics (NASDAQ:ARCT) had its price target trimmed by HC Wainwright from $12.00 to $9.00 in a research report sent to investors on Tuesday,Benzinga reports. The brokerage currently has a neutral rating on the biotechnology company’s stock. HC Wainwright also issued estimates for Arcturus Therapeutics’ Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($1.88) EPS, Q1 2026 earnings at ($0.71) EPS, Q2 2026 earnings at ($0.69) EPS, Q3 2026 earnings at ($0.66) EPS, Q4 2026 earnings at ($0.60) EPS, FY2026 earnings at ($2.19) EPS, FY2027 earnings at ($2.61) EPS, FY2028 earnings at ($1.48) EPS and FY2029 earnings at $1.72 EPS.

Several other analysts have also commented on ARCT. Citigroup lowered shares of Arcturus Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $49.00 to $12.00 in a research report on Thursday, October 23rd. Leerink Partners decreased their price target on shares of Arcturus Therapeutics from $63.00 to $54.00 and set an “outperform” rating for the company in a research note on Friday, August 22nd. BTIG Research dropped their price objective on Arcturus Therapeutics from $48.00 to $23.00 and set a “buy” rating on the stock in a research note on Wednesday, October 22nd. Wall Street Zen lowered Arcturus Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 25th. Finally, Guggenheim downgraded Arcturus Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 22nd. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $36.00.

Arcturus Therapeutics Trading Down 4.4%

ARCT stock opened at $7.77 on Tuesday. The stock has a market cap of $211.03 million, a P/E ratio of -3.16 and a beta of 2.47. The stock’s fifty day simple moving average is $16.40 and its two-hundred day simple moving average is $14.62. Arcturus Therapeutics has a 1-year low of $7.76 and a 1-year high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its earnings results on Monday, November 10th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.09) by $0.60. The firm had revenue of $17.15 million during the quarter, compared to analyst estimates of $17.47 million. Arcturus Therapeutics had a negative return on equity of 28.35% and a negative net margin of 68.35%. As a group, analysts forecast that Arcturus Therapeutics will post -2.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Arcturus Therapeutics

Institutional investors have recently made changes to their positions in the stock. Kennedy Capital Management LLC raised its stake in shares of Arcturus Therapeutics by 4.9% during the second quarter. Kennedy Capital Management LLC now owns 11,674 shares of the biotechnology company’s stock worth $152,000 after acquiring an additional 544 shares in the last quarter. Osaic Holdings Inc. boosted its stake in shares of Arcturus Therapeutics by 51.8% in the 2nd quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 738 shares in the last quarter. Tocqueville Asset Management L.P. grew its holdings in shares of Arcturus Therapeutics by 4.5% during the 1st quarter. Tocqueville Asset Management L.P. now owns 23,400 shares of the biotechnology company’s stock valued at $248,000 after purchasing an additional 1,000 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in Arcturus Therapeutics by 9.2% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 14,693 shares of the biotechnology company’s stock worth $156,000 after purchasing an additional 1,232 shares during the period. Finally, Bank of America Corp DE raised its position in Arcturus Therapeutics by 0.7% in the 2nd quarter. Bank of America Corp DE now owns 292,429 shares of the biotechnology company’s stock worth $3,805,000 after purchasing an additional 2,098 shares during the period. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.